SLRN Acelyrin
- 3.150
- -0.070-2.17%
- 3.150
- 0.0000.00%
Acelyrin News
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $5
Hold Rating Maintained for ACELYRIN, INC. Amidst Izokibep Study Setback and Revised Sales Projections
ACELYRIN Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
ACELYRIN, INC. (SLRN) Receives a Buy From Piper Sandler
Acelyrin Analyst Ratings
Hold Rating for ACELYRIN, INC. Amid Izokibep Trial Setback and Focus on Lonigutamab Development
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Vikram Purohit's Hold Rating on ACELYRIN, INC.: Awaiting Key Data and Trial Progress for Future Stock Movement
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
ACELYRIN Is Maintained at Neutral by HC Wainwright & Co.
Acelyrin Analyst Ratings
TD Cowen Maintains Acelyrin(SLRN.US) With Buy Rating
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $8 to $20
Acelyrin's Phase 3 Trial Progress and Uncertainties Lead to Hold Rating
ACELYRIN Is Maintained at Overweight by Wells Fargo
No Data